ILCA 15th Annual Conference Scientific Programme
The ILCA AC 2021 scientific programme will offer to participants with a large of different sessions dedicated to better prevent and treat liver cancer.
Scientific and medical experts from around the world will exchange the latest scientific advances and best practices in liver cancer research and care.
The 15th multidisciplinary Annual Conference format will present a mix of scientific and educational session and live debates and presentations.
A glance to some of the sessions that the ILCA Leadership is preparing:
Rare liver tumours workshop
Clinical aspects of fibrolamellar hepatocellular carcinoma
Ghassan K. Abou-Alfa, Medical Oncologist, Memorial Sloan Kettering Cancer Center, NY, US
Basic/Translation aspects of fibrolamellar hepatocellular carcinoma
Sandford Simon, Professor Biochemistry, biophysics, chemical biology and structural biology, The Rockefeller University, NY, US
Basic aspect of the hepatoblastoma
Jessica Zucman-Rossi, Professor of Medicine in Oncology, Director, Centre de Recherche des Cordeliers, Paris, France
Patient advocacy for patients with fibrolamellar HCC
Mark Furth, Scientific Director, Fibrolamellar Cancer Foundation, Greenwich, US
Clinical State of the Art
Past, present and future of transplant oncology
Vincenzo Mazzaferro, Professor of Surgery at the Department of Oncology, University of Milan and Director of the Gastro-Intestinal Surgery and Liver Transplantation Unit at the Istituto Nazionale Tumori (National Cancer Institute) of Milan, Italy.
Basic State of the Art
Telomeres and cancer
Maria Blasco, Director of the Spanish National Cancer Research Centre (CNIO). Head of the Telomeres and Telomerase Group – CNIO, Madrid, Spain
Basic Science Symposium
What has single cell genomics contributed to our understanding of liver cancer?
Single cell genomics and response to therapies in hepatocellular carcinoma
Xin Wei Wang, Senior Investigator and Deputy Chief, Laboratory of Human Carcinogenesis. Co-Director, Liver Cancer Program
Center for Cancer Research National Cancer Institute, NIH, Bethesda, US
Ploidy heterogeneity and HCC prevention
Hao Zhu, Associate Professor, Children’s Research Institute at UT Southwestern, Dallas, US